|
|
Acadia Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021
|
|
|
Acadia Pharmaceuticals to Present at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020
|
|
|
Acadia Pharmaceuticals Reports Third Quarter 2020 Financial Results
|
|
|
Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the 13th Clinical Trials on Alzheimer's Disease (CTAD) Conference
|
|
|
Acadia Pharmaceuticals to Announce Third Quarter 2020 Financial Results on November 4, 2020
|
|
|
The Lewy Body Dementia Association and Acadia Pharmaceuticals to Release Educational Version of the Highly Acclaimed Robin Williams Documentary, “Robin’s Wish”
|
|
|
Michael J. Fox Foundation and Acadia Pharmaceuticals Partner to Share Resources and Foster Dialogue on Cognitive Changes and Other Non-Motor Symptoms in Parkinson’s Disease
|
|
|
Acadia Pharmaceuticals Appoints Elizabeth Garofalo, M.D. to Board of Directors
|
|
|
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
|
|
|
ACADIA Pharmaceuticals Appoints Gudarz Davar, M.D., as Executive Vice President and Head of Research and Development
|
|
|
ACADIA Pharmaceuticals Acquires CerSci Therapeutics, Adds Novel Pain Program to Portfolio
|
|
|
ACADIA Pharmaceuticals to Present at The JMP Securities CNS Forum on August 19, 2020
|
|
|
ACADIA Pharmaceuticals Reports Second Quarter 2020 Financial Results
|
|
|
People with Dementia and Caregivers Share the Significant Burden of Visual Hallucinations and Paranoid Delusions, New Survey Highlights
|
|
|
ACADIA Pharmaceuticals to Announce Second Quarter 2020 Financial Results on August 5, 2020
|
|
|
ACADIA Pharmaceuticals Announces U.S. FDA Accepted for Filing the Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
|
|
|
ACADIA Pharmaceuticals Announces Top-line Results from the Phase 3 CLARITY Study Evaluating Pimavanserin for the Adjunctive Treatment of Major Depressive Disorder
|
|
|
ACADIA Pharmaceuticals Submits Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
|
|
|
ACADIA Pharmaceuticals to Present at the Goldman Sachs 41st Annual Global Healthcare Conference on June 9, 2020
|
|
|
ACADIA Pharmaceuticals Appoints Mark Schneyer as Senior Vice President, Business Development and Chief Business Officer
|
|
|
ACADIA Pharmaceuticals to Combine CLARITY-2 and CLARITY-3 Phase 3 Studies Evaluating Pimavanserin for the Adjunctive Treatment of Major Depressive Disorder
|
|
|
ACADIA Pharmaceuticals to Present Pimavanserin Clinical Data at the 2020 American Society of Clinical Psychopharmacology Virtual Annual Meeting
|
|
|
ACADIA Pharmaceuticals Reports First Quarter 2020 Financial Results
|
|
|
ACADIA Pharmaceuticals and Vanderbilt University Announce Exclusive License Agreement and Research Collaboration
|
|
|
ACADIA Pharmaceuticals to Present at Two Upcoming Virtual Investor Conferences
|
|
|
ACADIA Pharmaceuticals to Announce First Quarter 2020 Financial Results on May 7, 2020
|
|
|
ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Rare Pediatric Disease Designation for Trofinetide for the Treatment of Rett Syndrome
|
|
|
ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
|
|
|
ACADIA Pharmaceuticals to Present at the Cowen and Company 40th Annual Health Care Conference on March 2, 2020
|
|
|
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results on February 26, 2020
|
|
|
ACADIA Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 14, 2020
|
